People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avila Therapeutics Inc | — | Biotechnology | Series B | $45.0M | $893.0M | 2009 |
| Mercator Therapeutics, Inc. | — | Biotechnology | Seed | $2.0M | $88.8M | 2010 |
Roy R. Lobb at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roy R. Lobb on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amir Nashat | 1 | 14 |
| Bruce Booth | 1 | 12 |
| Daniel Lynch | 1 | 7 |
| Vicki Sato | 1 | 6 |
| Raj Parekh | 1 | 5 |
| Katrine Bosley | 1 | 4 |
| Henry Skinner | 1 | 4 |
| Christopher D.T. Guiffre | 1 | 2 |
| Michael F. Bigham | 1 | 2 |
| Mark D.T. Leuchtenberger | 1 | 1 |
| Henry R. Skinner | 1 | 1 |
| Amir R. Nashat | 1 | 1 |
| Raj R. Parekh | 1 | 1 |
| Bruce F. Booth | 1 | 1 |
| Vicki R. Sato | 1 | 1 |
| Daniel R. Lynch | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.